19 citations
,
January 2012 in “Dermatology” This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.
6 citations
,
August 2011 in “Anais Brasileiros de Dermatologia” This case report describes a 32-year-old man with therapy-resistant acneiform eruptions later diagnosed as vellus hair cysts, emphasizing the condition as a potential diagnostic consideration in similar cases.
2 citations
,
January 2011 in “Elsevier eBooks” This book reviews the various types of acne and acneiform conditions, as well as their treatment options, with expert insights from multiple fields.
2 citations
,
January 2004 in “Linchuang pifuke zazhi” In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.
June 2026 in “British Journal of Dermatology” In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.
In this case report, a patient on low-dose sorafenib for hepatocellular carcinoma developed a rare and severe facial acneiform eruption without other skin side effects, which improved only minimally with topical treatment.
December 2013 in “Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi” This case study highlights the importance of early diagnosis and treatment of acneiform eruptions associated with erlotinib in a 67-year-old male patient with non-small cell lung cancer to ensure patient compliance.
October 2016 in “International journal of medical research and review” This case report describes a 32-year-old male who developed acneiform eruptions one month after starting Minoxidil/Aminexil solution and Finasteride treatment for androgenic alopecia.
15 citations
,
December 2014 in “Dermatology and therapy” This study reports that sorafenib-associated facial acneiform eruption, mimicking chloracne, is a rare cutaneous adverse event which improved upon reducing or discontinuing the drug.
10 citations
,
October 2011 in “Dermatologica Sinica” This case report describes a patient who developed multiple skin reactions, including eczematous lesions and alopecia areata, during adalimumab treatment, but found no improvement in pustulosis palmoplantaris with different biologics.
5 citations
,
August 2011 in “Journal of the American Academy of Dermatology” This report describes a rare case of cyclophosphamide-associated neutrophilic folliculitis, suggesting its inclusion in differential diagnoses for acneiform eruptions.
16 citations
,
August 2017 in “Lupus” This case report and literature review highlights an unusual acne-like presentation of chronic cutaneous lupus erythematosus that doesn't improve with standard acne treatments, emphasizing the importance of considering CCLE in atypical acneiform eruptions.
1 citations
,
February 2020 in “The Journal of clinical investigation/The journal of clinical investigation” This study elucidates a mechanism for acne-like skin toxicity caused by EGFR/MEK inhibitors, involving an interaction with skin bacteria to trigger inflammation, which supports existing antibiotic treatment practices.
December 2025 in “Pediatric Dermatology” In this study, a 14-year-old girl developed Malassezia folliculitis and seborrheic dermatitis after starting trametinib, which improved with itraconazole treatment. The research underscores the importance of recognizing trametinib-related skin reactions and suggests managing them with antifungal therapy without necessarily discontinuing the medication.
1 citations
,
January 2026 in “International Journal of Dermatology” In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.
173 citations
,
July 2012 in “British Journal of Dermatology” This study found that the administration of the mutant BRAF inhibitor dabrafenib in patients with metastatic melanoma was associated with various skin lesions, including keratinocytic proliferation that sometimes showed low-grade malignancy features.
138 citations
,
February 2007 in “European journal of cancer” This review discusses the classification, pathogenesis, and management of skin, hair, nail, and mucosal changes due to EGFR inhibitors, emphasizing the importance of informing patients to improve therapy compliance.
116 citations
,
December 2003 in “Acta Dermato Venereologica” This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.
114 citations
,
January 2007 in “Drug Safety” This review discusses various adverse drug reactions affecting the skin, hair, and nails, emphasizing the importance of recognizing and reporting these reactions but reports no new clinical findings.
64 citations
,
February 1995 in “Journal of The American Academy of Dermatology” This report describes a case where hidradenitis suppurativa developed in a patient receiving lithium, adding to the recognized cutaneous side effects like psoriasis, acneiform lesions, and alopecia.
52 citations
,
October 2016 in “Clinics in Dermatology” This review discusses various drugs that can cause drug-induced acne, noting specific clinical and histopathologic features, but reports no new clinical findings.
43 citations
,
January 2014 in “Indian Journal of Dermatology” This study reported that EGFR inhibitor therapy in lung and head/neck cancer patients was associated with acneiform eruptions and severe skin dryness, which rarely necessitate discontinuation of treatment and can be managed symptomatically.
38 citations
,
January 2011 in “PubMed” This review discusses the range of cutaneous side-effects caused by EGFR inhibitors in cancer therapy and explores available treatment options, without reporting new clinical findings.
24 citations
,
January 2018 in “International Journal of Trichology” This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.
20 citations
,
January 2012 in “Indian Journal of Endocrinology and Metabolism” This study found that 76.19% of patients with acquired hypoparathyroidism had mucocutaneous manifestations, with common features including loss of hair and xerotic skin.
18 citations
,
May 2013 in “Journal of Dermatological Treatment” This study found that non-ablative fractional laser treatments in Korean patients had a low complication rate, with adverse events being temporary and not resulting in long-term consequences.
18 citations
,
October 2016 in “Clinics in Dermatology” This review discusses the challenges and complexities in diagnosing and managing acne and reports no new clinical findings; it emphasizes the need for careful evaluation to distinguish difficult acne from similar conditions.
17 citations
,
June 2020 in “British Journal of Dermatology” This study observed that oral mTOR inhibitors frequently cause dermatological side effects, such as mouth ulcers and acneiform eruptions, but these rarely require stopping the treatment.
17 citations
,
January 2019 in “Dermatologic Therapy” The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.